Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 19.6x which is lower than its 3-year average PE of 25.0x. The industry is trading close to its 3-year average PS ratio of 3.4x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 14 Jul 2026	UK£311.2b	UK£92.2b	UK£15.9b	19.3x	19.6x	3.4x
Thu, 11 Jun 2026	UK£321.0b	UK£92.2b	UK£15.8b	18x	20.3x	3.5x
Sat, 09 May 2026	UK£315.7b	UK£91.3b	UK£15.7b	17.6x	20.1x	3.5x
Mon, 06 Apr 2026	UK£362.2b	UK£91.4b	UK£15.7b	20x	23x	4x
Wed, 04 Mar 2026	UK£356.2b	UK£90.9b	UK£15.7b	21.7x	22.7x	3.9x
Fri, 30 Jan 2026	UK£321.8b	UK£88.3b	UK£14.4b	23.2x	22.3x	3.6x
Sun, 28 Dec 2025	UK£323.1b	UK£89.2b	UK£14.6b	21.8x	22.2x	3.6x
Tue, 25 Nov 2025	UK£327.0b	UK£90.7b	UK£14.8b	21.8x	22.1x	3.6x
Thu, 23 Oct 2025	UK£298.8b	UK£88.0b	UK£11.8b	20.7x	25.4x	3.4x
Sat, 20 Sep 2025	UK£271.9b	UK£87.6b	UK£11.7b	18.7x	23.2x	3.1x
Mon, 18 Aug 2025	UK£275.2b	UK£87.3b	UK£11.7b	21.9x	23.6x	3.2x
Wed, 16 Jul 2025	UK£259.0b	UK£86.8b	UK£10.7b	25.9x	24.3x	3x
Fri, 13 Jun 2025	UK£277.1b	UK£86.1b	UK£10.6b	27.4x	26.2x	3.2x
Sun, 11 May 2025	UK£258.4b	UK£87.2b	UK£10.7b	26.3x	24.2x	3x
Tue, 08 Apr 2025	UK£248.5b	UK£88.4b	UK£9.8b	28.2x	25.4x	2.8x
Thu, 06 Mar 2025	UK£291.7b	UK£88.0b	UK£9.6b	29.4x	30.3x	3.3x
Sat, 01 Feb 2025	UK£241.2b	UK£75.8b	UK£7.8b	33.7x	30.8x	3.2x
Mon, 30 Dec 2024	UK£224.3b	UK£75.3b	UK£7.8b	31.4x	28.9x	3x
Wed, 27 Nov 2024	UK£224.9b	UK£75.4b	UK£7.8b	31.4x	28.9x	3x
Fri, 25 Oct 2024	UK£250.4b	UK£72.5b	UK£9.1b	30x	27.6x	3.5x
Sun, 22 Sep 2024	UK£252.7b	UK£71.5b	UK£8.9b	37.8x	28.3x	3.5x
Tue, 20 Aug 2024	UK£275.4b	UK£72.5b	UK£9.0b	40.8x	30.5x	3.8x
Thu, 18 Jul 2024	UK£259.8b	UK£70.6b	UK£9.4b	35.8x	27.6x	3.7x
Sat, 15 Jun 2024	UK£267.2b	UK£71.6b	UK£9.6b	31.5x	27.9x	3.7x
Mon, 13 May 2024	UK£273.5b	UK£72.1b	UK£9.6b	37.4x	28.4x	3.8x
Wed, 10 Apr 2024	UK£241.5b	UK£70.7b	UK£9.7b	32.6x	24.9x	3.4x
Fri, 08 Mar 2024	UK£237.3b	UK£70.2b	UK£9.7b	30.9x	24.5x	3.4x
Sun, 04 Feb 2024	UK£237.0b	UK£69.8b	UK£9.5b	35.2x	24.8x	3.4x
Tue, 02 Jan 2024	UK£235.0b	UK£68.9b	UK£10.7b	35.5x	22x	3.4x
Thu, 30 Nov 2023	UK£223.8b	UK£69.0b	UK£10.7b	33.5x	21x	3.2x
Sat, 28 Oct 2023	UK£229.1b	UK£70.8b	UK£10.4b	54x	22.1x	3.2x
Mon, 25 Sep 2023	UK£247.8b	UK£70.5b	UK£10.4b	56.6x	23.9x	3.5x
Wed, 23 Aug 2023	UK£235.3b	UK£68.9b	UK£10.2b	53.5x	23.2x	3.4x
Fri, 21 Jul 2023	UK£236.0b	UK£67.4b	UK£7.8b	52x	30.1x	3.5x


GB Market	-1.34%
Healthcare	-6.68%
Pharma	-7.09%
Pharma	-7.09%

Company	Last Price	7D	1Y	Valuation
AGY Allergy Therapeutics	UK£0.074	12.1% +UK£50.7m	-7.5%	PS8.2x
HCM HUTCHMED (China)	UK£1.73	0.6% +UK£8.6m	-29.1%	PE4.4x
STX Shield Therapeutics	UK£0.063	2.5% +UK£1.6m	68.9%	PS1.8x
SAR Sareum Holdings	UK£0.23	4.5% +UK£1.4m	27.8%	PB26.7x
NFX Nuformix	UK£0.0017	3.0% +UK£130.5k	88.9%	PB2.7x

Announcement • 16h

GSK Plc Announces Positive Interim Results From AZUR-1 Phase II Trial Of Jemperli In dMMR/MSI-H Locally Advanced Rectal Cancer

GSK plc announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer. The single arm trial met its primary objective, showing a meaningful and sustained clinical complete response rate at 12 months (cCR12). These results support the potential for dostarlimab, if approved, to become the first immunotherapy capable of eliminating or delaying the need for chemotherapy, radiation and surgery for some patients in this population. Data to be shared with health authorities for regulatory review, including accelerated review in the US. Rectal cancer, a type of bowel cancer, affects around 730,000 people globally each year and approximately 5-10% of all rectal cancers have the dMMR/MSI-H subtype. Current standard of care typically includes chemotherapy, radiation, and surgery. While often effective, these treatments can profoundly impact a patient's quality of life, potentially leading to lifelong use of a colostomy bag, significant physiological dysfunction, and infertility. AZUR-1 results represent a substantial improvement compared to the historical standard of care and build on earlier research conducted in collaboration with Memorial Sloan Kettering Cancer Center, which first demonstrated the potential for dostarlimab to achieve clinical complete responses without other treatments in patients with dMMR/MSI-H locally advanced rectal cancer. In interim data, the safety and tolerability profile of dostarlimab was consistent with its well-characterised and manageable safety profile observed across solid tumours. Dostarlimab has received both Breakthrough Therapy and Fast Track designations from the US Food and Drug Administration (FDA) in this setting. GSK plans to share interim AZUR-1 data with global regulatory authorities to support review. Detailed results will be presented at a future scientific congress. Around 5-10% of rectal cancers are mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H). These tumours have a specific genetic characteristic where they are unable to properly repair DNA damage, leading to an accumulation of mutations. This unique biological feature often makes them highly responsive to immunotherapies like dostarlimab. These biomarkers are most commonly found in colorectal, endometrial and other gastrointestinal cancers, but can also be present in other solid tumours. AZUR-1 is a global, open-label, single-arm, registrational phase II trial evaluating dostarlimab monotherapy in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. The trial was designed to assess sustained clinical complete responses for 12 months (cCR12) and determine whether dostarlimab alone could enable patients to avoid chemotherapy, radiation and/or surgery. A total of 154 participants received nine cycles of dostarlimab over six months, administered as a 500 mg intravenous infusion every three weeks. Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK's ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of Jemperli alone and in combination with other therapies in gynaecologic, colorectal and head and neck cancers, as well as where there are opportunities for transformational outcomes. Jemperli was discovered by AnaptysBio Inc. and licensed to TESARO Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialisation, and manufacturing of Jemperli. Jemperli is not currently approved anywhere in the world for rectal cancer.

Announcement • Jul 01

Futura Medical Reports Highly Positive Data From WSD4000 Studies

Futura Medical reported the results from two studies on WSD4000: the Home User Test ('HUT') and the Placebo (Sham) Controlled Study. The positive results from both studies enhance the Company's belief in the commercial potential for WSD4000 and demonstrate that WSD4000 is superior to placebo (sham) thereby enabling it to proceed with the clinical study with high confidence of success. The Company expects to commence the clinical study by the end of 2026, subject to additional funding. WSD4000 was evaluated in 228 pre-, peri or post-menopausal women over a 4-week period. The results demonstrated that WSD4000 markedly improved sexual function from using the product. 78% of women reported a general improvement in all or most aspects of sex. 78% reported a more satisfying experience and 75% noticed having some increase in interest in having sex; 81% noticed an improvement to their overall sexual function. Overall, 68% of women rated the product 4 or 5 stars. 77% of participants had improved sexual experience after one use which increased to 84% after four uses. More specifically, after four uses: 83% of women experienced improved lubrication (wetness), 82% experienced improved genital sensation, 75% experienced improved arousal, 71% experienced faster arousal, 66% experienced greater ability to achieve orgasm, 61% experienced greater intensity of orgasm, 58% experienced less pain and discomfort during sex. The study also showed that, in general, the product was well tolerated, with only 18% of women experiencing a transient unpleasant sensory effect but many of those still wished to continue to use the product. The sensory effect described as unpleasant in some subjects can be mitigated when commercialised by clear consumer explanation highlighting that this is part of the mode of action of the product. The vast majority (84%) of women in the study claimed to like the sensory feel and lack of aroma of the product. A placebo ('sham' in US regulatory terminology) controlled study was conducted in order to design the most cost-effective clinical study to deliver a statistically significant and clinically meaningful result. WSD4000 was evaluated versus a placebo control in an "in-clinic" cross-over study in 33 pre- and post-menopausal women. WSD4000 was statistically superior to placebo in each of the key measures (arousal, genital sensation and lubrication) at 1 min, 2 min, 3 min, 5 min, 10 min and 15 min intervals. The results give the Company a high degree of confidence that WSD4000 will have superior efficacy to placebo (sham) in the pivotal clinical study and that subject numbers in the study will be at a cost-effective level. Independent research data conducted in the US with 1,000 subjects shows that 60% of women have suffered from at least one symptom of impaired sexual response and function in the prior twelve months. Only 1 in 4 of those impacted women seek professional help. Few women (13%) experience an improvement in symptoms over time and for 37% symptoms get worse over time. Currently, there is no known regulatory approved topical treatment globally for impaired sexual response and function in women that is available over the counter. Market research conducted by Ipsos showed 60% of women have experienced symptoms of sexual dysfunction over the last twelve months and 49% of women want to treat their symptoms. Current US female population between the ages of 22 and 75 is 113 million, of which 68 million experience symptoms. WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Poolbeg Pharma PLC has completed a Follow-on Equity Offering in the amount of £3.5 million.

GSK Plc Announces Positive Interim Results From AZUR-1 Phase II Trial Of Jemperli In dMMR/MSI-H Locally Advanced Rectal Cancer

ECO Animal Health Group plc to Report Fiscal Year 2026 Results on Jul 15, 2026

Ionis Pharmaceuticals Provides Update on CARDIO-TTRansform Phase 3 Trial of Eplontersen in Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

STX: Japan Trial Progress Will Drive Future Earnings Upside

HUTCHMED (China) Limited Receives NMPA Approval For ORPATHYS For Treatment Of Gastric Cancer Patients With MET Amplification

HLN: Lower Forward P E Assumptions Will Pressure Future Share Price

Futura Medical Reports Highly Positive Data From WSD4000 Studies

New minor risk - Financial data availability

Sareum Holdings PLC Publishes Phase 1 Clinical Data on SDC-1801 in British Journal Of Clinical Pharmacology

Hikma Pharmaceuticals PLC Welcomes FDA Approval of Guardant360 Liquid CDx

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

New major risk - Shareholder dilution